pharmaphorum

DECEMBER 8, 2021

Tanja Dowe is the CEO of Debiopharm Innovation Fund, the strategic investment arm of the Swiss pharmaceutical company Debiopharm. A former entrepreneur and strategy and transaction consultant, she steers the fund to invest in start-ups with disruptive technologies that transform the pharmaceutical industry. . About the author.

Pharmaceutical Companies 74

Pharmaceutical Companies Pharmaceutical Companies 74

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 95

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 95

pharmaphorum

JUNE 14, 2021

In this episode of our Health Innovators series, Paul Tunnah interviews Graeme Duncan, CEO of specialty pharmaceutical company Advanz Pharma. Graeme discusses his career in the life sciences industry and how Advanz Pharma positions itself as the go-to partner for companies commercialising complex medicines in Europe.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 23, 2025

Skip to main content Monday 23 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

Pharmaceutical Technology

OCTOBER 5, 2022

Bringing an end to a 13-year deliberation on a whistleblower lawsuit, Biogen recently agreed to pay a $900 million settlement , amidst increased government alertness on pharmaceutical fraud. In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings.

Documentation 59

Documentation Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JUNE 25, 2025

Skip to main content Wednesday 25 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

NOVEMBER 26, 2020

Since the start of the year, pharmaceutical companies have been riding a rollercoaster of challenges. Dr Paul Tunnah founded pharmaphorum in 2009, which combines industry leading publications ( www.pharmaphorum.com ) with a specialist strategy and content marketing/communications consultancy ( www.pharmaphorumconnect.com ).

Communication 111

Communication Pharmaceutical Companies Pharmaceutical Companies 111

Eye on FDA

SEPTEMBER 28, 2022

FDA published notice recently that the Office of Prescription Drug Promotion (OPDP) was proposing some new research related to the promotion of medicines by pharmaceutical companies. That is particularly true given that the 2009 framework has only been partially addressed by the agency.

Communication 69

Communication Pharmaceutical Companies Pharmaceutical Companies 69

European Pharmaceutical Review

JANUARY 25, 2024

According to Eurostat, only 57 percent of people in the 55-74 age group use the internet regularly, and only 54 percent of Europeans possess basic digital skills The Pharmaceutical Group of the European Union (PGEU) presents a compelling argument against the proposed POD policy. Article 63 EMA (29 January 2020).

Packaging 98

Packaging Documentation Communication Pharmaceutical Companies 98

pharmaphorum

DECEMBER 28, 2022

In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. So, how do smaller pharmaceutical companies at the cutting edge get ready for their acquisition milestone, so they maximise their value and attractiveness?

Pharmaceutical Manufacturing 119

Pharmaceutical Manufacturing Documentation Pharmaceutical Companies Pharmaceutical Companies 119

European Pharmaceutical Review

AUGUST 24, 2023

This heightened focus from regulators is shifting the type of deals pharmaceutical companies are willing to execute, Baral noted. These mega deals created behemoth companies that needed to spread capital too thin and included redundancies due to unrealised synergies.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 98

pharmaphorum

JUNE 20, 2025

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Drug Development 52

Drug Development Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Drug Development 52

Drug Development Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines 71

Vaccines Diabetes Pharmaceutical Companies Pharmaceutical Companies 71

PharmaState Academy

DECEMBER 18, 2024

Name Email Phone Number Company Department Designation 1 / 20 How can scientific communication contribute to better collaboration between pharmaceutical companies and research institutions? a) 2009 b) 2010 c) 2012 d) 2014 13 / 20 What is the primary goal of scientific communication in pharma marketing?

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 16, 2025

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

Eye on FDA

JANUARY 9, 2022

As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceutical companies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist. in November 2009.

Communication 64

Communication Documentation Labelling Pharmaceutical Companies 64

Pharma Marketing Network

MARCH 25, 2023

Pharmaceutical advertising is a crucial aspect of promoting and marketing drugs to the public. With the increase in competition, it has become essential for pharmaceutical companies to find the most effective methods of advertisement to reach their target audience. ” Pharmacy and Therapeutics, 2009.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Express Pharma

SEPTEMBER 6, 2023

What’s more, with many key biologics scheduled to lose patent protection in this decade, Indian pharmaceutical companies ought to seize this opportunity and leverage innovative technologies to introduce quality and way more affordable biosimilars in the domestic as well as global markets.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Syner-G

AUGUST 9, 2022

IMPACT (now part of Syner-G BioPharma Group) has been providing Regulatory Affairs support to a mid-size pharmaceutical company since 2009. Even though this company has a Regulatory Affairs Department, their rapid growth over the years has made “in-sourcing” of help a necessity.

Labelling 40

Labelling Pharmaceutical Companies Pharmaceutical Companies 40

Syner-G

AUGUST 21, 2022

In 2009, IMPACT (now part of Syner-G BioPharma Group) was contracted by a mid-size global pharmaceutical company to prepare 2 Phase 3 clinical study reports (CSRs) for a biologic agent for the treatment of Crohn’s disease. Download a PDF of this case study. Establishment of a Long-Term Medical Writing Partnership.

Documentation 40

Documentation Pharmaceutical Companies Pharmaceutical Companies 40

Eye on FDA

JULY 7, 2020

For some years CDER published its Guidance Agenda to include a guidance on the use of links to third party websites by pharmaceutical companies. OPDP has indicated in the past that the use of sponsored links without risk information is a no-no. This item disappeared from the agenda, however, and no draft guidance was issued.

Communication 52

Communication Documentation Labelling Pharmaceutical Companies 52

Pharmaceutical Technology

OCTOBER 5, 2008

“The business integration from 2005 to 2007 of the two separate companies to form the joint Daiichi Sankyo created one of Japan’s biggest pharmaceutical companies.” ” “The use of generic drugs is low in Japan, but health costs are increasing and the government has to do something to reduce costs.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Labelling Diabetes 40

Pharmaceutical Technology

MAY 11, 2008

Pharmaceutical companies, regulatory agencies and governments are becoming increasingly concerned about fraud and counterfeiting throughout the pharmaceutical supply chain, especially with the cost of drugs going up.

Packaging 40

Packaging Labelling Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 78

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 78

pharmaphorum

JUNE 11, 2025

Skip to main content Wednesday 11 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes 87

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 87

pharmaphorum

JUNE 6, 2025

Skip to main content Friday 6 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

pharmaphorum

JUNE 11, 2025

Skip to main content Wednesday 11 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes 91

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 91

pharmaphorum

JULY 14, 2021

He was referring to his business’ share of misconduct related fines that, between 2009 and 2017, topped $342 billion across the US and Europe. It’s killing us.” As the sector looks to maintain its momentum, it must be wary that positive messaging and increased scrutiny does not end up as a recipe for a hard fall.

Communication 105

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 105

pharmaphorum

MARCH 30, 2021

Camilla has a well-recognised track record working with various multinational companies, including AstraZeneca, Novartis and Allergan. About the author.

Hospitals 111

Hospitals Communication Drug Development Pharmaceutical Companies 111

PharmaShots

FEBRUARY 21, 2023

The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients. Other radiotherapies under the company's pipeline include Humalutin and Alpha37. The company is evaluating Iomab-B in a P-III clinical trial (SIERRA) in patients with relapsed or refractory acute myeloid leukemia (AML).

Dosage 56

Dosage Labelling Pharmaceutical Companies Immunization 56

Pharma Marketing Network

JUNE 11, 2020

So, this was back in 2009, and I hosted a Halloween party at my house, and I decided to dress up as Hunter S. You know, in November 2009, the FDA held a public hearing about the promotion of Food and Drug Administrative Related Regulated Medical Products, using the internet and social media tools. So, I didn’t look so bad.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Diabetes 52